Skip to main content
Journal cover image

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.

Publication ,  Journal Article
Burns, DK; Chiang, C; Welsh-Bohmer, KA; Brannan, SK; Culp, M; O'Neil, J; Runyan, G; Harrigan, P; Plassman, BL; Lutz, M; Lai, E; Haneline, S ...
Published in: Alzheimers Dement (N Y)
2019

INTRODUCTION: Alzheimer's disease (AD) is a continuum with neuropathologies manifesting years before clinical symptoms; thus, AD research is attempting to identify more disease-modifying approaches to test treatments administered before full disease expression. Designing such trials in cognitively normal elderly individuals poses unique challenges. METHODS: The TOMMORROW study was a phase 3 double-blind, parallel-group study designed to support qualification of a novel genetic biomarker risk assignment algorithm (BRAA) and to assess efficacy and safety of low-dose pioglitazone to delay onset of mild cognitive impairment due to AD. Eligible participants were stratified based on the BRAA (using TOMM40 rs 10524523 genotype, Apolipoprotein E genotype, and age), with high-risk individuals receiving low-dose pioglitazone or placebo and low-risk individuals receiving placebo. The primary endpoint was time to the event of mild cognitive impairment due to AD. The primary objectives were to compare the primary endpoint between high- and low-risk placebo groups (for BRAA qualification) and between high-risk pioglitazone and high-risk placebo groups (for pioglitazone efficacy). Approximately 300 individuals were also asked to participate in a volumetric magnetic resonance imaging substudy at selected sites. RESULTS: The focus of this paper is on the design of the study; study results will be presented in a separate paper. DISCUSSION: The design of the TOMMORROW study addressed many key challenges to conducting a dual-objective phase 3 pivotal AD clinical trial in presymptomatic individuals. Experiences from planning and executing the TOMMORROW study may benefit future AD prevention/delay-of-onset trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Alzheimers Dement (N Y)

DOI

EISSN

2352-8737

Publication Date

2019

Volume

5

Start / End Page

661 / 670

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Burns, D. K., Chiang, C., Welsh-Bohmer, K. A., Brannan, S. K., Culp, M., O’Neil, J., … Saunders, A. M. (2019). The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimers Dement (N Y), 5, 661–670. https://doi.org/10.1016/j.trci.2019.09.010
Burns, Daniel K., Carl Chiang, Kathleen A. Welsh-Bohmer, Stephen K. Brannan, Meredith Culp, Janet O’Neil, Grant Runyan, et al. “The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.Alzheimers Dement (N Y) 5 (2019): 661–70. https://doi.org/10.1016/j.trci.2019.09.010.
Burns DK, Chiang C, Welsh-Bohmer KA, Brannan SK, Culp M, O’Neil J, et al. The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimers Dement (N Y). 2019;5:661–70.
Burns, Daniel K., et al. “The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.Alzheimers Dement (N Y), vol. 5, 2019, pp. 661–70. Pubmed, doi:10.1016/j.trci.2019.09.010.
Burns DK, Chiang C, Welsh-Bohmer KA, Brannan SK, Culp M, O’Neil J, Runyan G, Harrigan P, Plassman BL, Lutz M, Lai E, Haneline S, Yarnall D, Yarbrough D, Metz C, Ponduru S, Sundseth S, Saunders AM. The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimers Dement (N Y). 2019;5:661–670.
Journal cover image

Published In

Alzheimers Dement (N Y)

DOI

EISSN

2352-8737

Publication Date

2019

Volume

5

Start / End Page

661 / 670

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences